The Moncton Hospital

Az itteni vizsgálatok

Miről szól a helyszín 24 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Áttétes emlőrák6 vizsgálat
• Tüdőrák6 vizsgálat
• Krónikus limfoid leukémia (CLL)2 vizsgálat
• Krónikus mieloid leukémia (CML)2 vizsgálat
• Mielóma multiplex2 vizsgálat
• Akut mieloid leukémia (AML)1 vizsgálat
• Elhízás1 vizsgálat
• Köpenysejtes limfóma1 vizsgálat
• Méhtestrák1 vizsgálat
• Mielodiszplasztikus szindróma (MDS)1 vizsgálat
• Szarkóma1 vizsgálat
• Tripla negatív emlőrák1 vizsgálat
• és még 2

Fázis

• 3. fázis15 vizsgálat
• 2. fázis5 vizsgálat

Állapot

• Fut, nem toboroz13 vizsgálat
• Lezárult6 vizsgálat
• Toboroz4 vizsgálat
• Leállították1 vizsgálat

Fő szponzor

• National Cancer Institute (NCI)8 vizsgálat
• Canadian Cancer Trials Group6 vizsgálat
• Hoffmann-La Roche3 vizsgálat
• Alliance for Clinical Trials in Oncology2 vizsgálat
• Pfizer2 vizsgálat
• és még 3

Futó vizsgálatok

• Toboroz

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· 3. fázis· Hoffmann-La Roche· Forrás

• Toboroz

  Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

  NCT06182774· 3. fázis· Canadian Cancer Trials Group· Forrás

  Contact: Nizar Abdel-Samad

• Toboroz

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· 3. fázis· Pfizer· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  NCT05894239· 3. fázis· Hoffmann-La Roche· Forrás

• Toboroz

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

  NCT05646862· 3. fázis· Hoffmann-La Roche· Forrás

• Fut, nem toboroz

  A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

  NCT05654623· 3. fázis· Pfizer· Forrás

• Fut, nem toboroz

  Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

  NCT03914612· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

  NCT03055013· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

  NCT03057106· 2. fázis· Canadian Cancer Trials Group· Forrás

• Fut, nem toboroz

  Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

  NCT02954874· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás

• Fut, nem toboroz

  Economic Analysis of Alliance A041202 CLL Study

  NCT02414022· Canadian Cancer Trials Group· Forrás

• Fut, nem toboroz

  Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

  NCT01886872· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

  NCT01415752· 2. fázis· Eastern Cooperative Oncology Group· Forrás

• Fut, nem toboroz

  Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

  NCT01522976· 2. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

  NCT00499330· Alliance for Clinical Trials in Oncology· Forrás

• Fut, nem toboroz

  Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

  NCT00070499· 2. fázis· National Cancer Institute (NCI)· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Áttétes emlőrák2 toboroz
• Mielóma multiplex2 toboroz

Lezárt vizsgálatok

• Lezárult

  An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network

  NCT04564079· Exactis Innovation· Forrás

• Leállították

  Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

  NCT03199885· 3. fázis· National Cancer Institute (NCI)· Forrás

• Lezárult

  Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

  NCT02630693· 2. fázis· Canadian Cancer Trials Group· Forrás

• Lezárult

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· 3. fázis· EMD Serono Research & Development Institute, Inc.· Forrás

• Lezárult

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· 3. fázis· Canadian Cancer Trials Group· Forrás

• Lezárult

  Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

  NCT00819208· Canadian Cancer Trials Group· Forrás

• Lezárult

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· 3. fázis· National Cancer Institute (NCI)· Forrás